Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation
NCT00445263 · Hospital Avicenne · PHASE4 · terminated · last registry update 2015-02-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Because of inclusion delay” | – | Registry record, Hospital Avicenne |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGB3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-02-25Results posted on the registry: National Cancer Institute (NCI), cilengitide + temozolomide (NCT00085254)
- 2016-02-12Results posted on the registry: The Medicines Company, Bivalirudin + Heparin (NCT01087723)
- 2015-12-18Also stopped (withdrawn): University of Rochester, Abciximab (NCT00178451)
- 2015-12-14Results posted on the registry: Merck KGaA, Darmstadt, Germany, EMD 525797 (NCT00848510)
- 2015-12-14Results posted on the registry: EMD Serono, EMD 525797 + EMD 525797 (NCT01360840)
- 2015-07-21Also stopped (terminated): Martin-Luther-Universität Halle-Wittenberg, Cilengitide + Temozolomide (NCT01517776)
- 2015-04-28Also stopped (terminated): National Cancer Institute (NCI), Cilengitide (NCT01122888)
- 2015-03-26Also stopped (withdrawn): St. Louis University, Abciximab + Placebo (NCT01932554)
- 2014-12-08Results posted on the registry: EMD Serono, Cilengitide (2-times weekly) + cilengitide (5-times weekly) (NCT00813943)
- 2014-11-04Results posted on the registry: EMD Serono, Cilengitide + Temozolomide (NCT00689221)
- 2014-09-30Results posted on the registry: Merck KGaA, Darmstadt, Germany, Cilengitide + Cilengitide (NCT00842712)
- 2014-07-08Phase 3 first posted: Boehringer Ingelheim, Full dose TNK-tPA + Half dose TNK-tPA (NCT02181985)
- 2014-05-15Also stopped (terminated): National Cancer Institute (NCI), etaracizumab + bevacizumab (NCT00684996)
- 2014-04-30Results posted on the registry: Merck KGaA, Darmstadt, Germany, Cilengitide 2000 mg once weekly + Cilengitide 2000 mg twice weekly (NCT00705016)
- 2014-04-25Also stopped (terminated): SOS Attaque Cérébrale, alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip) (NCT02016547)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision